

CLAIMS

1. Use of antisense oligonucleotide complementary to human miR-203b-3p microRNA (SEQ: ID: NO.3), wherein said oligonucleotide having sequence (SEQ: ID: NO. 4) or sequence with an identity percentage equal to at least 70% with respect to said sequence (SEQ: ID: NO. 4), preferably at least 75%, more preferably at least 80%, and wherein said oligonucleotide comprises a central sequence of 8 nucleotides 5'-UUCUUAAC-3', for the manufacture of a medicament for the treatment of psoriasis-induced itching.
2. The use according to claim 1, wherein the first uracil (U) of the central sequence UUCUUAAC corresponds to the base in the ninth nucleotide in the oligonucleotide for use according to the invention and the last cytosine (C) of the central sequence corresponds to the base in the sixteenth nucleotide in the oligonucleotide for use according to the invention.
3. The use according to claim 1 or 2, wherein said central sequence 5'-UUCUUAAC-3' within said sequence (SEQ: ID: NO. 4) binds the central portion 5'-GUUAAGAA-3' of the sequence (SEQ: ID: NO.3) of human miR-203b-3p microRNA.
4. The use according to any one of the preceding claims, wherein said antisense oligonucleotide is in the form of antagomir of the human miR-203b-3p microRNA (SEQ: ID: NO.3).
5. The use according to claim 1, wherein said antisense oligonucleotide with an identity percentage equal to at least 70% with respect to said sequence (SEQ: ID: NO. 4) is selected from the group that comprises the following sequences:
 - 5'-ACA ACU UGU UCU UAA CAU GUC CA-3' (SEQ: ID: NO. 5)
 - 5'-UCA CGU ACU UCU UAA CAU UUA CA-3' (SEQ: ID: NO. 6)
 - 5'-AUG ACU GGU UCU UAA CAG UAG UA-3' (SEQ: ID: NO. 7)
 - 5'-AGC UCA GGU UCU UAA CAG UUC AA-3' (SEQ: ID: NO. 8)
 - 5'-UUA AGU GGU UCU UAA CAG CUA CA-3' (SEQ: ID: NO. 9)
 - 5'-UGC UGA GGU UCU UAA CAG ACC AA-3' (SEQ: ID: NO. 10)
 - 5'-UCA AAC GGU UCU UAA CAG UUC AA-3' (SEQ: ID: NO. 11)
 - 5'-UCC CGU GGU UCU UAA CAG CUC GA-3' (SEQ: ID: NO. 12)

5'-UGC AGC GGU UCU UAA CAG UUA AA-3' (SEQ: ID: NO. 13).

6. The use according to any one of the preceding claims, wherein said psoriasis is selected from plaque psoriasis, pustular psoriasis, guttate psoriasis, inverse psoriasis and erythrodermic psoriasis.

5 7. The use according to claim 6, wherein said psoriasis is plaque psoriasis.

8. Phospholipid vesicle that comprises at least an antisense oligonucleotide as defined in any of the claims from 1 to 5.

9. Phospholipid vesicle according to claim 8, comprising at least an oligonucleotide selected from the group of oligonucleotides having sequence (SEQ: ID: NO. 5), (SEQ: ID: NO. 6), (SEQ: ID: NO. 7), (SEQ: ID: NO. 8), (SEQ: ID: NO. 9), (SEQ: ID: NO. 10), (SEQ: ID: NO. 11), (SEQ: ID: NO. 12) and (SEQ: ID: NO. 13).

10. Phospholipid vesicle according to claim 8, comprising the oligonucleotide having sequence (SEQ: ID: NO. 4) and at least a further oligonucleotide selected from the group of oligonucleotides having sequence (SEQ: ID: NO. 5), (SEQ: ID: NO. 6), (SEQ: ID: NO. 7), (SEQ: ID: NO. 8), (SEQ: ID: NO. 9), (SEQ: ID: NO. 10), (SEQ: ID: NO. 11), (SEQ: ID: NO. 12) and (SEQ: ID: NO. 13).

11. Phospholipid vesicle according to any one of claims 8 to 10, selected from liposomes, phytosomes, micelles or mixtures thereof.

12. Phospholipid vesicle according to claim 11, in the form of a liposome.

20 13. Phospholipid vesicle according to any one of claims 8 to 12, for use in the treatment of itching induced by plaque psoriasis, pustular psoriasis, guttate psoriasis, inverse psoriasis and erythrodermic psoriasis.

14. Phospholipid vesicle according to claim 13, wherein said psoriasis is plaque psoriasis.

25 15. Pharmaceutical composition which comprises at least a phospholipid vesicle according to any one of claims 8 to 14 and one or more pharmaceutically suitable or pharmaceutically acceptable excipient(s).

16. Pharmaceutical composition according to claim 15, in the form of cream, powder, or ointment.

30 17. Composition according to claim 16, in the form of cream for topical use.

18. Pharmaceutical composition according to any one of claims 15 to 17, for application by means of a medicated patch.

19. Pharmaceutical composition according to any one of claims 15 to 18, for use in the treatment of itching induced by plaque psoriasis, pustular psoriasis, guttate psoriasis,
5 inverse psoriasis and erythrodermic psoriasis.

20. Pharmaceutical composition according to claim 19, wherein said psoriasis is plaque psoriasis.